Caribou's most advanced program is called CB-010, and it's being investigated in a phase 1 clinical trial for treating relapsed or refractory B-cell non-Hodgkin's lymphoma. On July 13, the biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results